BFS
DNA icon

Bradley Foster & Sargent’s Ginkgo Bioworks DNA Stock Holding History

Bradley Foster & Sargent’s Portfolio DNA Stock Details DNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,860
Closed -$232K – 431
2022
Q3 		$232K Hold
1,860
– – 0.01% 394
2022
Q2 		$177K Buy
1,860
+126
+7% +$15.4K ﹤0.01% 428
2022
Q1 		$280K Buy
+1,734
New +$338K 0.01% 414

Other funds holding DNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACG
Anchorage Capital Group New York $450M AUM 41.75% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
GA
General Atlantic New York $2.91B AUM 24.21% 1-Year Est. Return

Bradley Foster & Sargent's DNA Position: Q4 2022 in Review

Bradley Foster & Sargent sold out of Ginkgo Bioworks (DNA) in Q4 2022, closing a stake of 1,860 shares — an estimated $232K sold.

Bradley Foster & Sargent first reported a position in DNA in Q1 2022 and held it in 3 quarters. The position peaked at $280K in Q1 2022. 320 funds tracked by Wall St. Rank hold DNA as of Q4 2022.

  • Bradley Foster & Sargent reported no remaining Ginkgo Bioworks position as of Q4 2022 after selling out during the quarter.
  • Bradley Foster & Sargent sold 1,860 Ginkgo Bioworks shares in Q4 2022, an estimated $232K.
  • Bradley Foster & Sargent first reported a position in Ginkgo Bioworks in Q1 2022 and held it in 3 quarters.
  • Bradley Foster & Sargent's Ginkgo Bioworks position peaked at $280K in Q1 2022.
  • 320 funds tracked by Wall St. Rank held Ginkgo Bioworks as of Q4 2022.

Based on Bradley Foster & Sargent's 13F filing for Q4 2022, filed 14 Feb 2023.